Chronic Renal Insufficiency Cohort (CRIC) - GWAS

The Chronic Renal Insufficiency Cohort (CRIC study) was established in 2001 by the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) to improve the understanding of the relationship between chronic kidney disease and cardiovascular disease. The goals of the CRIC Study are to examine risk factors for progression of chronic kidney disease and cardiovascular disease among patients with chronic kidney disease and to develop predictive models to identify high-risk subgroups, informing future treatment trials and increasing application of available preventive therapies. Data available at dbGaP include genotype data for 3527 participants released in version 1. Plasma metabolomics and plasma proteomics data will be available at dbGaP in "Chronic Renal Insufficiency Cohort (CRIC) Study Metabolomics and Proteomics". Additional phenotypic, clinical, and outcomes data are available at the NIDDK Central Repository and can be linked to data available at dbGaP.

More than 330 manuscripts have been published, reporting on the effects of a broad range of risk factors (from molecular biomarkers of disease pathways to clinical, demographic, and behavioral characteristics) on the progression of CKD and other health consequences. The full CRIC bibliography can be found at http://cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/bibliography-2024-2023.

• Study Weblinks:
  • CRIC
• Study Design:
  • Case Set
• Study Type:
  • Cohort
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 3596
• Subject Sample Telemetry Report (SSTR)

• Clinical Trials
  • NCT00304148

Participants are no longer being enrolled in the study. The following Inclusion/Exclusion Criteria were followed at the time of participant recruitment.

Inclusion for participants enrolled in phase 1: 21 to 74 years; Age Based eGFR: 21-44 years 20-70 ml/min/1/73m2), 45-64 years 20-60 ml/min/1/73m2, 65-74 years 20-50 ml/min/1/73m2.

Inclusion for participant enrolled in phase 3: 45 to 79 years; eGFR 45-70 ml/min; Primarily proteinuric CKD

Exclusion: Institutionalized, unable or unwilling to provide informed consent, participant appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee, NYHA Class III or IV heart failure at baseline, known cirrhosis based on patient self-report, known ADPKD, known HIV infection and/or AIDS based on patient self-report, present participation in the AASK Cohort Study, pregnant women.

2001: design of the study began
2004-2008: recruitment of participants conducted resulting in over 3000 enrolled participants
2008: phase 2 of the study began, follow-up of cohort
2013: Phase 3 of the study began, new recruitment and continued follow-up of the existing cohort
2013- 2015: Recruitment of Phase 3 cohort (n=1560 additional participants)
2018: Phase 4 of the study began, continued follow-up of the cohort
2023: Phase 5 of the study began, participant follow-up extended for 3 additional years

• Primary Phenotype: Chronic Renal Insufficiency

• Principal Investigator, Scientific and Data Coordinating Center, CRIC Steering Committee Chair
  • Laura Dember, MD. University of Pennsylvania, Philadelphia, PA, USA.
• Principal Investigator, Scientific and Data Coordinating Center
  • Amanda Anderson, PhD, MPH. University of Alabama at Birmingham, Birmingham, AL, USA.
• Principal Investigators, Clinical Center
  • Debbie Cohen, MBBCH. University of Pennsylvania, Philadelphia, PA, USA.
  • Lawrence J. Appel, MD, MPH. The Johns Hopkins University, Baltimore, MD, USA.
  • Mahboob Rahman, MD, MS. University Hospitals of Cleveland, Cleveland, OH, USA.
  • Panduranga Rao, MD. University of Michigan at Ann Arbor, Ann Arbor, MI, USA.
  • James P. Lash, MD. University of Illinois, Chicago, IL, USA.
  • Jing Chen, MD, MSSc, MSc. Tulane University, New Orleans, LA, USA.
  • Alan S. Go, MD. Kaiser Permanente, Oakland, CA, USA.
• Program Officers, NIDDK
  • Tracy Rankin, PhD, MPH. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Afshin Parsa, MD, MPH. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.